Ngan H, Lai C L, Fan S T, Lai E C, Yuen W K, Tso W K
Department of Diagnostic Radiology, University of Hong Kong.
Clin Radiol. 1993 May;47(5):315-20. doi: 10.1016/s0009-9260(05)81446-1.
Eighty patients with inoperable hepatocellular carcinoma (HCC) were treated by transcatheter arterial chemoembolization using an emulsion of Lipiodol and Cisplatin. In 59 patients, gelfoam embolization was also given. The tumour size ranged from 0.5 cm to 33 cm in maximum diameter with the median diameter being 8 cm. The chemoembolization sessions were repeated every 1 1/2 to 3 months. The number of sessions the patients underwent varied from 1 to 11, with the mean number of sessions being 3.7. The HCC either disappeared completely or decreased in size in 44 patients (55%). In patients having an HCC of 12 cm or less in size, 31 out of 41 (75.6%) who had the addition of gelfoam demonstrated decrease in tumour size, while seven out of 11 (63.6%) without the addition of gelfoam demonstrated decrease in tumour size. In patients having an HCC of more than 12 cm in size, only six out of 18 (33.3%) who had the addition of gelfoam demonstrated reduction in tumour size and none of the 10 patients without the addition of gelfoam responded. Thus, HCCs of 12 cm or less in size responded better than larger ones to chemoembolization (P < 0.0001) while the addition of gelfoam enhanced the response (P = 0.039). The 1 year survival rate for the 80 patients was 53% and the 2 years survival rate was 38%. The median survival was 13 months. For patients having an HCC of 12 cm or less in size, the 1 year and 2 year survival rates were 69% and 47% respectively.(ABSTRACT TRUNCATED AT 250 WORDS)
80例无法手术切除的肝细胞癌(HCC)患者接受了使用碘油和顺铂乳剂的经导管动脉化疗栓塞治疗。59例患者还进行了明胶海绵栓塞。肿瘤最大直径范围为0.5厘米至33厘米,中位直径为8厘米。化疗栓塞疗程每1.5至3个月重复一次。患者接受的疗程数从1次到11次不等,平均疗程数为3.7次。44例患者(55%)的HCC完全消失或缩小。在HCC大小为12厘米或更小的患者中,41例接受明胶海绵栓塞的患者中有31例(75.6%)肿瘤缩小,而11例未接受明胶海绵栓塞的患者中有7例(63.6%)肿瘤缩小。在HCC大小超过12厘米的患者中,18例接受明胶海绵栓塞的患者中只有6例(33.3%)肿瘤缩小,10例未接受明胶海绵栓塞的患者均无反应。因此,大小为12厘米或更小的HCC对化疗栓塞的反应比更大的肿瘤更好(P<0.0001),而添加明胶海绵可增强反应(P = 0.039)。80例患者的1年生存率为53%,2年生存率为38%。中位生存期为13个月。对于HCC大小为12厘米或更小的患者,1年和2年生存率分别为69%和47%。(摘要截短至250字)